# **Special Issue**

# Current State-of-Art of Extracellular Vesicles for Targeting Gene Therapy in Neurological Disorders

# Message from the Guest Editors

Extracellular vesicles (EVs) are achieving considerable accomplishments in targeted gene therapy, opening a new frontier to develop gene delivery strategies for neurological disorders. In addition to the cargo of different proteins, lipids, and nucleic acid. EVs isolated from patients diagnosed with Alzheimer's and Parkinson's disease and recently also multiple sclerosis show an altered genetic cargo in the form of miRNA. This has boosted the EVs' role as biomarkers in the diagnosis of human neurological diseases. However, so far, most EVs studies have been performed using in vitro and in vivo models. Standardization of methodologies and testing across human neurodisorders still represent key challenges. This Special Issue aims to harvest the latest advanced studies of EVs in diagnosing and treating central nervous system diseases, sharing knowledge and data with readers and scientists working in this discipline to foster an effective and safe clinical translation of these unique intercellular delivery vehicles.

#### **Guest Editors**

Dr. Nicola Orefice

Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA

Prof. Dr. Markus Kipp

Department of Anatomy, Rostock University Medical Center, 18055 Rostock, Germany

#### Deadline for manuscript submissions

closed (31 July 2023)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/74212

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

#### **Editor-in-Chief**

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

## **Journal Rank:**

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

